SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

• NASDAQ: $SWTX
• Notified: $46.55
• 06:30 EDT